{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:20:06Z","timestamp":1788326406407,"version":"build-2803163510"},"reference-count":37,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["HT9425-23-1-0351"],"award-info":[{"award-number":["HT9425-23-1-0351"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["HT9425-23-1-0232"],"award-info":[{"award-number":["HT9425-23-1-0232"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"award":["HT9425-23-1-0351"],"award-info":[{"award-number":["HT9425-23-1-0351"]}],"id":[{"id":"https:\/\/ror.org\/0447fe631","id-type":"ROR","asserted-by":"publisher"}]},{"award":["HT9425-23-1-0232"],"award-info":[{"award-number":["HT9425-23-1-0232"]}],"id":[{"id":"https:\/\/ror.org\/0447fe631","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R03CA282712"],"award-info":[{"award-number":["R03CA282712"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"award":["R03CA282712"],"award-info":[{"award-number":["R03CA282712"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012870","name":"Ovarian Cancer Alliance of Greater Cincinnati","doi-asserted-by":"publisher","award":["PRIV0201"],"award-info":[{"award-number":["PRIV0201"]}],"id":[{"id":"10.13039\/100012870","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012870","name":"Ovarian Cancer Alliance of Greater Cincinnati","doi-asserted-by":"publisher","award":["PRIV0219"],"award-info":[{"award-number":["PRIV0219"]}],"id":[{"id":"10.13039\/100012870","id-type":"DOI","asserted-by":"publisher"}]},{"award":["PRIV0201"],"award-info":[{"award-number":["PRIV0201"]}],"id":[{"id":"https:\/\/ror.org\/010r6td27","id-type":"ROR","asserted-by":"publisher"}]},{"award":["PRIV0219"],"award-info":[{"award-number":["PRIV0219"]}],"id":[{"id":"https:\/\/ror.org\/010r6td27","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-18-160-16"],"award-info":[{"award-number":["IRG-18-160-16"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"award":["IRG-18-160-16"],"award-info":[{"award-number":["IRG-18-160-16"]}],"id":[{"id":"https:\/\/ror.org\/02e463172","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019823","name":"University of Maryland, Baltimore","doi-asserted-by":"crossref","award":["UM1TR004926"],"award-info":[{"award-number":["UM1TR004926"]}],"id":[{"id":"10.13039\/100019823","id-type":"DOI","asserted-by":"crossref"}]},{"award":["UM1TR004926"],"award-info":[{"award-number":["UM1TR004926"]}],"id":[{"id":"https:\/\/ror.org\/04rq5mt64","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>The failure of current therapeutics to elicit a durable response in metastatic ovarian cancer patients highlights the urgent need to develop more effective treatment strategies. In this study, we demonstrate that the anti-diabetic drug metformin exerts cytotoxic effects across a broad panel of ovarian cancer cell lines. Transcriptomic analyses revealed that, in addition to reducing cell viability and proliferation, metformin modulates pathways associated with metastatic progression, including cell migration, extracellular matrix remodeling, and cellular responses to chemotherapeutic agents. Consistent with these molecular changes, metformin significantly impaired ovarian cancer cell migration and invasion through Matrigel. Furthermore, metformin diminished the ability of ovarian cancer cells to form multicellular aggregates, a key property that facilitates successful metastatic dissemination within the peritoneal cavity. Although metformin produced only a modest increase in carboplatin sensitivity, systematic screening of FDA-approved drugs identified several agents whose efficacy was enhanced by metformin, including drugs not currently used to treat ovarian cancer. Collectively, these findings demonstrate that metformin suppresses metastatic phenotypes and enhances therapeutic vulnerability in ovarian cancer cells, supporting its potential repurposing as a combination therapy to improve treatment outcomes in ovarian cancer.<\/jats:p>","DOI":"10.3390\/ijms27177779","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:48:36Z","timestamp":1788256116000},"page":"7779","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metformin Suppresses Metastatic Potential and Sensitizes Ovarian Cancer Cells to Chemotherapeutics"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-989X","authenticated-orcid":false,"given":"Megha J.","family":"Pandya","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5114-8156","authenticated-orcid":false,"given":"Ayokunnumi","family":"Ogunsanya","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2126-4192","authenticated-orcid":false,"given":"Adedoyin","family":"Ajibade","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7130-7793","authenticated-orcid":false,"given":"Achuth","family":"Padmanabhan","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA"},{"name":"University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian Cancer: A Review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"v181","DOI":"10.1093\/annonc\/mdj978","article-title":"Challenges for chemotherapy in ovarian cancer","volume":"17","author":"Ozols","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_3","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","first-page":"304","article-title":"Mechanisms of chemotherapy resistance in ovarian cancer","volume":"5","author":"Ortiz","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13048-026-02115-9","article-title":"Chemoresistance in gynecologic cancers: Mechanistic insights and emerging platforms to overcome drug failure","volume":"19","author":"Garg","year":"2026","journal-title":"J. Ovarian Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Al Khzem, A.H., Gomaa, M.S., Alturki, M.S., Tawfeeq, N., Sarafroz, M., Alonaizi, S.M., Al Faran, A., Alrumaihi, L.A., Alansari, F.A., and Alghamdi, A.A. (2024). Drug Repurposing for Cancer Treatment: A Comprehensive Review. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202410.2321.v1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.biochi.2025.03.002","article-title":"Metformin\u2019s anticancer odyssey: Revealing multifaceted mechanisms across diverse neoplastic terrains\u2014A critical review","volume":"233","author":"Pal","year":"2025","journal-title":"Biochimie"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/s41416-023-02204-2","article-title":"Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?","volume":"128","author":"Lord","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","article-title":"Metformin pathways: Pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet. Genom."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.tem.2019.07.015","article-title":"Metformin as Anti-Aging Therapy: Is It for Everyone?","volume":"30","author":"Soukas","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis","volume":"3","author":"DeCensi","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Noto, H., Goto, A., Tsujimoto, T., and Noda, M. (2012). Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033411"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.21037\/atm-20-1060","article-title":"Metformin and ovarian cancer: The evidence","volume":"8","author":"Urpilainen","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"117276","DOI":"10.1016\/j.lfs.2020.117276","article-title":"Inhibition of mTORC1\/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C","volume":"243","author":"Yuan","year":"2020","journal-title":"Life Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41598-018-38004-5","article-title":"Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities","volume":"9","author":"Riaz","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101026","DOI":"10.1016\/j.neo.2024.101026","article-title":"Metformin use and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada","volume":"56","author":"Kaur","year":"2024","journal-title":"Neoplasia"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yao, K., Zheng, H., and Li, T. (2022). Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.942380"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e133247","DOI":"10.1172\/jci.insight.133247","article-title":"Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer","volume":"5","author":"Brown","year":"2020","journal-title":"JCI Insight"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2025.02.001","article-title":"Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial","volume":"194","author":"Romero","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.gendis.2020.11.017","article-title":"Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine","volume":"9","author":"Guo","year":"2022","journal-title":"Genes Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tang, D., Chen, M., Huang, X., Zhang, G., Zeng, L., Zhang, G., Wu, S., and Wang, Y. (2023). SRplot: A free online platform for data visualization and graphing. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0294236"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: Historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","article-title":"Cellular and Molecular Mechanisms of Metformin Action","volume":"42","author":"LaMoia","year":"2021","journal-title":"Endocr. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/cas.13849","article-title":"Novel application of metformin combined with targeted drugs on anticancer treatment","volume":"110","author":"Deng","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101945","DOI":"10.1016\/j.tranon.2024.101945","article-title":"Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect","volume":"44","author":"Zhu","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1158\/1078-0432.CCR-12-2777","article-title":"Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines","volume":"19","author":"Morgillo","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"93825","DOI":"10.18632\/oncotarget.21225","article-title":"Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-13-2613","article-title":"Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal","volume":"20","author":"Li","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/ijc.29113","article-title":"Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation","volume":"136","author":"Groenendijk","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1007\/s00726-014-1838-4","article-title":"Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK\/JNK-mediated NF-kappaB-dependent pathway that reduces uPA and MMP-9 expression","volume":"46","author":"Hsieh","year":"2014","journal-title":"Amino Acids"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3892\/or.2015.3805","article-title":"Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells","volume":"33","author":"Chen","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ariaans, G., Jalving, M., Vries, E.G., and Jong, S. (2017). Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3230-8"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.18632\/oncotarget.488","article-title":"Metformin-induced preferential killing of breast cancer initiating CD44+CD24\u2212\/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts","volume":"3","author":"Dorca","year":"2012","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/15384047.2014.1002366","article-title":"Metformin: A modulator of bevacizumab activity in cancer? A case report","volume":"16","author":"Indraccolo","year":"2015","journal-title":"Cancer Biol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7779\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:30:22Z","timestamp":1788323422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":37,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177779"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177779","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}